Working draft — Scientific review: pending | Regulatory review: pending | Not for external clinical or promotional use without independent verification
Prescriber / researcher information only. Not for patient promotion.
Back to Prescriber Hub
5
Prescriber OnlyLast reviewed: April 2026

NWPT-SM32300 Scientific Information for Prescribers

Provide a separate prescriber-only scientific module on NWPT-SM32300.

Prescriber-onlyCSR pending

Learning Objectives

Understand what NWPT-SM32300 is
Understand what is known from the IB
Understand what remains investigational
Understand what claims require CSR/stat-shell confirmation
Know how to discuss the product without promoting it

Core Content

NWPT-SM32300 is NW PharmaTech's investigational 300 mg cannabidiol oral softgel.

Product-specific data should be considered investigational unless supported by final CSR, validated clinical data or formal regulatory review.

Key Takeaways

  • 1NWPT-SM32300 is an investigational 300 mg CBD oral softgel
  • 2Phase 1 used 600 mg and 900 mg dose sessions
  • 3All comparative claims require CSR validation
  • 4Safety cautions include liver risk, interactions, pregnancy, driving
  • 5Do not use promotional language about the product

Knowledge Check

Q1. Which of the following claims about NWPT-SM32300 can be made without CSR validation?

Downloadable Tools

Claim validation checklist

Checklist for verifying NWPT-SM32300-specific claims against CSR status

checklist

Product-specific FAQ

Frequently asked questions about NWPT-SM32300 for prescribers

card

Tools are provided as templates for clinical practice. Adapt to your clinic's specific requirements.

References

  1. [1]NW PharmaTech. NWPT-SM32300 Investigator's Brochure. Internal document.
  2. [2]NW PharmaTech. Phase 1 Comparative Bioavailability Study Protocol.
Module 4: Living EvidenceModule 6: Patient Selection

This material is educational and non-promotional. It does not constitute medical advice, prescribing advice, or a recommendation to use any medicine. Any use of an unlicensed medicine requires patient-specific clinical justification, informed consent, monitoring, pharmacovigilance and compliance with applicable regulatory requirements.